Brain tumour immunology and therapy group

News archive for Brain tumour immunology and therapy group

BORTEM-17 interim analysis results and small molecule inhibitor targeting CSPG4/NG2 in glioblastoma at American Association for Cancer Research (AACR 2024) April 5-10, 2024
We congratulate Marianne Hjellvik Hannisdal for this accolade, winning best poster prize at the medical faculty‘s research day, with over 30 talented phd fellows who presented their excellent research projects in the form of poster presentations!
Glioblastoma (GBM) is malignant brain tumor, where the best available treatment extends survival by approximately 15 months. The tumor has a diffusely infiltrative growth pattern and a microenvironment that makes it difficult to achieve a long-lasting treatment response. Understanding the mechanisms that lead to GBM treatment resistance is imperative for development of novel therapies.
We congratulate Maria Tennefos Sørbø who has completed and passed her master's thesis in medical school. The study was conducted in the period 2019-2021.
2020 evolved into an annus horribilis for everyone, manifested by physical distancing and social isolation, disrupted work routines and for many, tragic loss of livelihood and loved ones.
"Immunological, Molecular and Imaging Biomarkers of Malignant Progression in Brain Cancer: Improving Precision Neuro-Oncology"
Best PhD prize 2019 – Andrea Gras Navarro - “Towards Natural Killer cellular Immunotherapy for glioblastoma. KIR-HLA ligand interaction and proteasome inhibitors to potentiate efficacy"
The brain cancer immunology and therapy group will participate at the science fair in Bergen, together with the patient organization for brain tumors, hjernesvulstforeningen.
Our new paper "Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival" has been published in British Journal of Cancer.
The research laboratory for brain cancer immunology and therapy at the Department of Biomedicine has received the secretary general of the Brain-Tumour Society Rolf Ledal to discuss current and future research projects.
This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.
110 participants from Norway, Denmark, Sweden, Finland, Netherlands, Germany, and Poland converged on Nidelven in sunny Trondheim for this year´s SNOG conference on brain tumours.
Aminur Rahman, PhD, has been awarded the American Association for Cancer Research (AACR) Scholar-in-Training Award
Bortezomib as chemosensitizer for glioblastoma patients with unmethylated MGMT promoter: Phase IB/II clinical trial and mechanisms of therapeutic efficacy
We congratulate CCBIO associate Agnete Engelsen with the faculty award for best PhD dissertation!